Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.30 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.30 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14297329 | 0.92 | HPGD (0.35) | HDAC6HDAC4HDAC1LMNAMCHR1 | |
| SCHEMBL2221964 | 0.83 | HDAC6 (0.41) | HDAC6HDAC4HDAC1HDAC3HDAC8 | |
| SCHEMBL12517334 | 0.81 | HDAC4 (0.39) | HDAC6HDAC4HDAC1MCHR1HDAC8 | |
| SCHEMBL14297246 | 0.81 | MCHR1 (0.34) | HDAC6HDAC4HDAC1LMNAMCHR1 | |
| SCHEMBL2345961 | 0.79 | MCHR1 (0.33) | HDAC6HDAC4HDAC1LMNAMCHR1 | |
| SCHEMBL14243944 | 0.78 | LMNA (0.45) | HDAC6HDAC4HDAC1LMNAHDAC3 | |
| SCHEMBL14243906 | 0.77 | HDAC1 (0.41) | HDAC6HDAC4HDAC1LMNAHDAC3 | |
| SCHEMBL2270279 | 0.72 | HDAC4 (0.36) | HDAC6HDAC4HDAC1LMNAMCHR1 | |
| SCHEMBL14297312 | 0.70 | GAA (0.44) | HDAC6HDAC1LMNAGAATSHR | |
| SCHEMBL14297309 | 0.70 | HPGD (0.39) | HDAC6HDAC4HDAC1LMNAHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013009812-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC (US) | 2013-01-17 | — | — | WO | claimed |
| US-20120322827-A1 | COMPOUNDS AND METHODS | TEMPERO PHARAMCEUTICALS. INC. | 2012-12-20 | — | — | US | claimed |
| WO-2013009812-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC (US) | 2013-01-17 | — | — | WO | disclosed |
| US-20120322827-A1 | COMPOUNDS AND METHODS | TEMPERO PHARAMCEUTICALS. INC. | 2012-12-20 | — | — | US | disclosed |
| US-20120322827-A1 | COMPOUNDS AND METHODS | TEMPERO PHARAMCEUTICALS. INC. | 2012-12-20 | — | — | US | disclosed |
| EP-2523560-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011088187-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088187-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322827-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | HDAC6 1991/4885HDAC4 2086/4885HDAC1 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.